Table 2 Estimated Hazard ratios (HR) and corresponding 95% confidence intervals regarding progression-free survival in the one-stage meta-analysis
References | Estimated HR | Estimated 95% CI |
|---|---|---|
CDKN2A/B deletion (homozygous or heterozygous) versus wild-type | ||
Sievers et al. [37] | 6.83 | 4.20–11.10 |
Driver et al. [6] | 10.47 | 6.05–18.11 |
Wang et al. [46] | 5.42 | 3.89–7.55 |
Khan et al. [16] | 8.91 | 5.81–14.23 |
Entire IPD Cohort | 6.83 | 5.50–8.47 |
Homozygous CDKN2A/B deletion versus wild-type | ||
Sievers et al. [37] | 6.83 | 4.20–11.10 |
Driver et al. [6] | 16.18 | 6.10–42-96 |
Wang et al. [46] | 6.79 | 4.49–10.26 |
Khan et al. [16] | 12.32 | 6.25–24.31 |
Entire IPD Cohort | 8.35 | 6.36–10.95 |
Heterozygous CDKN2A/B deletion versus wild-type | ||
Driver et al. [6] | 9.30 | 5.00–17.30 |
Wang et al. [46] | 4.19 | 2.52–6.97 |
Khan et al. [16] | 7.43 | 4.08–13.52 |
Entire IPD Cohort | 5.52 | 3.99–7.62 |